Seroatlas · Human Serome Atlas

EPGN

Epigen

Also known as: ALGV3072, EPG, EPGN_HUMAN, PRO9904

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6UW88
Gene: EPGN
Ensembl: ENSG00000182585
Chromosome: 4
Canonical length: 154 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins
Subcellular location: Nucleoplasm,Vesicles,Cytosol
Secretome location: Secreted in other tissues

OverviewNCBI Gene

The protein encoded by this gene is a member of the epidermal growth factor family. Members of this family are ligands for the epidermal growth factor receptor and play a role in cell survival, proliferation and migration. This protein has been reported to have high mitogenic activity but low affinity for its receptor. Expression of this transcript and protein have been reported in cancer specimens of the breast, bladder, and prostate. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]

Canonical amino-acid sequenceUniProt

154 residues, UniProt reviewed canonical sequence.

>Q6UW88|EPGN
     1  MALGVPISVY LLFNAMTALT EEAAVTVTPP ITAQQGNWTV NKTEADNIEG PIALKFSHLC
    61  LEDHNSYCIN GACAFHHELE KAICRCFTGY TGERCEHLTL TSYAVDSYEK YIAIGIGVGL
   121  LLSGFLVIFY CYIRKRCLKL KSPYNVCSGE RRPL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against EPGN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.53
Highest tissue expression: 46 nTPM

Expression across tissuesHPA

Tissue

esophagus: 46 nTPM
vagina: 9.5 nTPM
cervix: 9 nTPM
skin: 3.4 nTPM
tonsil: 3.2 nTPM
salivary gland: 3 nTPM

Single-cell type

esophageal apical cells: 306 nCPM
hematopoietic stem cells: 134 nCPM
esophageal suprabasal cells: 106 nCPM
megakaryocyte-erythroid progenitors: 87 nCPM
innate lymphoid cells: 51 nCPM
ocular epithelial cells: 31 nCPM

Immune cell

basophil: 0.4 nTPM
neutrophil: 0.4 nTPM
naive B-cell: 0.2 nTPM
naive CD4 T-cell: 0.2 nTPM
classical monocyte: 0.1 nTPM
intermediate monocyte: 0.1 nTPM

Brain region

cerebral cortex: 2.4 nTPM
cerebellum: 1.9 nTPM
white matter: 1.8 nTPM
midbrain: 1.7 nTPM
hippocampal formation: 1.5 nTPM
medulla oblongata: 1.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.57
gnomAD pLI: 0
gnomAD missense Z: 0.06
DepMap mean gene effect: 0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

EGF-like domain

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads EPGN as an antibody target. Whether an autoantibody or antibody against EPGN could matter depends on whether native EPGN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

EPGN is annotated as secreted, so native EPGN circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label EPGN as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...